[1]张恒林,吴克第,王声威,等.绝经后骨质疏松症患者血清CCL2，CX3CL1 和CXCL10 的水平表达及对骨折发生的预测价值[J].现代检验医学杂志,2024,39(04):165-169.[doi:10.3969/j.issn.1671-7414.2024.04.030]
　ZHANG Henglin,WU Kedi,WANG Shengwei,et al.Expression Levels of Serum CCL2, CX3CL1 and CXCL10 in Postmenopausal Osteoporosis Patients and Their Predictive Value for Fracture Occurrence[J].Journal of Modern Laboratory Medicine,2024,39(04):165-169.[doi:10.3969/j.issn.1671-7414.2024.04.030]
点击复制

绝经后骨质疏松症患者血清CCL2，CX3CL1 和CXCL10 的水平表达及对骨折发生的预测价值()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第39卷
期数:
2024年04期
页码:
165-169
栏目:
论著
出版日期:
2024-07-15

文章信息/Info

Title:
Expression Levels of Serum CCL2, CX3CL1 and CXCL10 in Postmenopausal Osteoporosis Patients and Their Predictive Value for Fracture Occurrence
文章编号:
1671-7414（2024）04-165-05
作者:
张恒林; 吴克第; 王声威; 刘景新
（海南西部中心医院骨科，海南儋州 571799）
Author(s):
ZHANG Henglin;  WU Kedi;  WANG Shengwei;  LIU Jingxin
（Department of Orthopedics,Hainan West Central Hospital, Hainan Danzhou 571799，China）
关键词:
绝经后骨质疏松症; 骨折; CC 趋化因子配体2; CX3C 趋化因子配体1; CXC 趋化因子配体10
分类号:
R591.1；R392.11
DOI:
10.3969/j.issn.1671-7414.2024.04.030
文献标志码:
A
摘要:
目的 探讨血清CC 趋化因子配体2（CC chemokine ligand 2，CCL2）、CX3C 趋化因子配体1（CX3Cchemokine ligand 1，CX3CL1）及CXC 趋化因子配体10（CXC chemokine ligand 10，CXCL10）在绝经后骨质疏松症（postmenopausal osteoporosis，PMOP）患者中的表达及其联合骨折风险评估工具（fracture risk assessment tool，FRAX）预测骨折发生的价值。方法 选取2022 年1 月～ 2023 年6 月海南西部中心医院收治的PMOP 患者120 例，根据其发生骨折情况分为骨折组（n=52）和未骨折组（n=68），根据FRAX 评分检查分为骨折高风险组（n=73）和骨折低风险组（n=47）。比较各组血清CCL2，CX3CL1 及CXCL10 水平。多因素Logistic 回归分析影响PMOP 患者发生骨折的危险因素，绘制ROC曲线分析CCL2，CX3CL1及CXCL10联合FRAX评分预测PMOP发生骨折的价值。结果 骨折组血清CCL2（134.98±32.24 pg/ml），CX3CL1（186.25 ± 41.60 pg/ml）及CXCL10（223.47 ± 56.43 pg/ml）水平均明显高于未骨折组（82.26±17.30 pg/ml，105.23 ±23.78 pg/ml，151.47 ± 43.14 pg/ml），差异具有统计学意义（t=11.503，13.452，7.923， 均P<0.001）。骨折高风险组血清CCL2（119.70 ± 37.56 pg/ml），CX3CL1（161.43 ± 53.79 pg/ml） 及CXCL10（204.06 ± 61.41pg/ml） 水平均明显高于低风险组（82.43 ± 17.23 pg/ml，107.55 ± 24.75 pg/ml，149.45 ± 42.50pg/ml），差异具有统计学意义（t=6.377，6.436，5.327，均P<0.001）。多因素Logistic 回归分析显示，血清CCL2，CX3CL1 及CXCL10 水平升高是影响PMOP 患者发生骨折的危险因素。ROC 曲线显示，CCL2，CX3CL1及CXCL10 联合FRAX 评分预测PMOP 发生骨折的AUC（95%CI）最大[0.951（0.892 ～ 0.993）]，其敏感度和特异度分别为98.2%，85.6%。结论 血清CCL2，CX3CL1 及CXCL10 水平升高是影响PMOP 患者发生骨折的危险因素，联合FRAX 评分对骨折具有较好的预测价值。
Abstract:
Objective To investigate the expression of serum CC chemokine ligand 2 (CCL2), CX3C chemokine ligand 1 (CX3CL1) and CXC chemokine ligand 10 (CXCL10) in postmenopausal osteoporosis (PMOP) patients and the value of combination with fracture risk assessment tool (FRAX) in predicting fracture occurrence. Methods A total of 120 patients with PMOP admitted to Hainan West Central Hospital from January 2022 to June 2023 were selected, and they were divided into fracture group (n=52) and non-fracture group (n=68). According to the FRAX score examination, they were divided into a highrisk fracture group (n=73) and a low-risk fracture group (n=47). The levels of serum CCL2, CX3CL1 and CXCL10 in each group were compared. Multivariate Logistic regression was used to analyze the fracture risk factors in PMOP patients. ROC curve was drawn to analyze the value of CCL2, CX3CL1 and CXCL10 combined with FRAX score in predicting fracture of PMOP. Results The levels of serum CCL2 (134.98±32.24 pg/ml), CX3CL1 (186.25 ± 41.60 pg/ml) and CXCL10 (223.47 ± 56.43 pg/ml) in the fracture group were higher than those in the non-fracture group (82.26±17.30 pg/ml, 105.23±23.78 pg/ml, 151.47 ± 43.14 pg/ml), and the differences were statistically significant (t=11.503, 13.452, 7.923, all P<0.001). The levels of serum CCL2 (119.70 ± 37.56 pg/ml), CX3CL1 (161.43 ± 53.79 pg/ml) and CXCL10 (204.06 ± 61.41pg/ml) in the high-risk group for fractures were higher than those in the low-risk group (82.43 ± 17.23 pg/ml, 107.55 ± 24.75 pg/ml, 149.45 ± 42.50pg/ml), and the differences were statistically significant (t=6.377, 6.436, 5.327, all P<0.001). Multivariate Logistic regression analysis showed that elevated levels of serum CCL2, CX3CL1 and CXCL10 were risk factors for fractures in PMOP patients. The ROC curve showed that the combination of CCL2, CX3CL1 and CXCL10 combined with FRAX scores predicted the highest AUC (95%CI) for PMOP fractures [0.951(0.892 ～ 0.993)], with sensitivity and specificity of 98.2% and 85.6%, respectively. Conclusion The increased levels of serum CCL2, CX3CL1 and CXCL10 are risk factors for fracture in PMOP patients, and the combination with FRAX score has a good predictive value for fracture.

参考文献/References:

[1] WALKER M D, SHANE E. Postmenopausal osteoporosis[J]. New England Journal of Medicine, 2023, 389(21): 1979-1991.
[2] 吴婉, 郦忆文, 梁冰, 等. FRAX? 评估国内骨质疏松性骨折的应用现状分析[J]. 中华全科医学, 2022,20(10): 1751-1754. WU Wan, LI Yiwen, LIANG Bing, et al. Analysis of the current status of FRAX? application in evaluating osteoporotic fractures in China [J]. Chinese Journal of General Practice, 2022, 20(10): 1751-1754.
[3] YUAN Shiguo, HU Hongling, WANG Xinjia, et al. Bindarit reduces bone loss in ovariectomized mice by inhibiting CCL2 and CCL7 expression via the NF-κB signaling pathway[J]. Orthopaedic Surgery, 2022, 14(6): 1203-1216.
[4] LU Zhihua, ZHANG Aihua, DAI Yan. CX3CL1 deficiency ameliorates inflammation, apoptosis and accelerates osteogenic differentiation, mineralization in LPS-treated MC3T3-E1 cells via its receptor CX3CR1 [J]. Anatomischer Anzeiger, 2023, 246: 152036.
[5] FISCHER V, RAGIPOGLU D, DIEDRICH J, et al. Mast cells trigger disturbed bone healing in osteoporotic mice[J]. Journal of Bone and Mineral Research, 2022, 37(1): 137-151.
[6] 中华医学会骨质疏松和骨矿盐疾病分会. 原发性骨质疏松症诊疗指南(2022)[J]. 中华骨质疏松和骨矿盐疾病杂志, 2022, 15(6): 573-611. Chinese Society of Osteoporosis and Bone Mineral research. Guidelines for the diagnosis and treatment of primary osteoporosis (2022) [J]. Chinese Journal of Osteoporosis and Bone Mineral Research, 2022, 15(6): 573-611.
[7] 中华医学会骨科学分会, 张英泽, 胡永成, 等. 骨质疏松性骨折诊疗指南(2022 年版)[J]. 中华骨科杂志,2022, 42(22): 1473-1491. Chinese Orthopaedic Association, ZHANG Yingze, HU Yongcheng, et al. Guidelines for the diagnosis and treatment of osteoporotic fractures (2022 edition) [J]. Chinese Journal of Orthopaedics, 2022, 42(22): 1473-1491.
[8] 赵国阳, 王波, 陈志平, 等. 中老年骨量异常人群血清骨代谢生化指标与FRAX骨折风险相关性分析[J].中国骨质疏松杂志, 2020, 26(9): 1282-1286. ZHAO Guoyang, WANG Bo, CHEN Zhiping, et al. Relationship between serum biochemical indexes of bone metabolism and FRAX fracture risk in middleaged and elder people with abnormal bone mass [J]. Chinese Journal of Osteoporosis, 2020, 26(9): 1282-1286.
[9] LIU Jie, XIA Ronglin, LI Chen, et al. The prevalence of osteoporosis in postmenopausal women in urban Tianjin, China and its related factors[J]. Menopause the Journal of the North American Menopause Society, 2023, 30(7): 774-780.
[10] 陈浩, 侍管, 唐海, 等. 应用FRAX 预测绝经后女性骨折风险的回顾性研究[J]. 中华骨质疏松和骨矿盐疾病杂志, 2023, 16(4): 297-304. CHEN Hao, SHI Guan, TANG Hai, et al. Fracture risk assessment tool on predicting fracture risk in postmenopausal women：a retrospective study [J]. Chinese Journal of Osteoporosis and Bone Mineral Research, 2023, 16(4): 297-304.
[11] IANTOMASI T, ROMAGNOLI C, PALMINI G, et al. Oxidative stress and inflammation in osteoporosis: molecular mechanisms involved and the relationship with microRNAs[J]. International Journal of Molecular Sciences, 2023, 24(4): 3772.
[12] 姚琼璐, 杨雨清, 徐涛涛. 免疫微环境对绝经后骨质疏松症的影响[J]. 中国骨质疏松杂志, 2023, 29(6):902-907, 921. YAO Qionglu, YANG Yuqing, XU Taotao. Effect of immune microenvironment on postmenopausal osteoporosis [J]. Chinese Journal of Osteoporosis, 2023, 29(6): 902-907, 921.
[13] WANG Qingchan, HUANG Ping, XIA Chenjie, et al. Network pharmacology-based strategy to investigate pharmacological mechanism of Liuwei Dihuang Pill against postmenopausal osteoporosis[J]. Medicine, 2022, 101(47): e31387.
[14] FENG Xinzhe, ZHU Shanbang, QIAO Junjie, et al. CX3CL1 promotes M1 macrophage polarization and osteoclast differentiation through NF-κB signaling pathway in ankylosing spondylitis in vitro[J]. Journal of Translational Medicine, 2023, 21(1): 573.
[15] MINBO Jiang, FENG Chen, WEN Hongli, et al. Upregulated and hypomethylated genes are causative factors and diagnostic markers of osteoporosis[J]. American Journal of Translational Research, 2023, 15(10): 6042-6057.
[16] HU Yaqian, WANG Long, ZHAO Zhuojie, et al. Cytokines CCL2 and CXCL1 may be potential novel predictors of early bone loss[J]. Molecular Medicine Reports, 2020, 22(6): 4716-4724.
[17] 宋茜茜, 尹飞, 郭淑芹, 等. 2 型糖尿病合并骨质疏松症患者血清CX3CL1, CCL3, CCL4 与糖脂代谢、骨密度及骨代谢标志物的相关性[J]. 疑难病杂志,2022, 21(8): 828-833. SONG Qianqian, YIN Fei, GUO Shuqin, et al. Correlation of serum CX3CL1,CCL3,CCL4 with glucose and lipid metabolism,bone mineral density and bone metabolism markers in patients with type 2 diabetes and osteoporosis [J]. Chinese Journal of Difficult and Complicated Cases, 2022, 21(8): 828-833.
[18] 段小凯, 秦贵军. 绝经女性2 型糖尿病患者血清CXC 趋化因子配体8, 10 和Irisin 蛋白的表达及意义[J]. 中国老年学杂志, 2019, 39(6): 1315-1317. DUAN Xiaokai, QIN Guijun. Expression and significance of CXC chemokine ligand 8,10 and Irisin protein in serum of postmenopausal women with type 2 diabetes[J]. Chinese Journal of Gerontology, 2019, 39(6): 1315-1317.
[19] CHAVDA S, CHAVDA B, DUBE R. Osteoporosis screening and fracture risk assessment tool: its scope and role in general clinical practice[J]. Cureus, 2022, 14(7): e26518.

相似文献/References:

[1]于彩霞,巩云霏,闫　苏,等.血清视黄醇结合蛋白4 及骨桥蛋白与绝经后骨质疏松症的相关性研究[J].现代检验医学杂志,2020,35(02):112.[doi:10.3969 ／ j.issn.1671-7414.2020.02.031]
　YU Cai-xia,GONG Yun-fei,YAN Su,et al.Relationship between Serum Retinol Binding Protein 4 and Osteopontin andPostmenopausal Osteoporosis[J].Journal of Modern Laboratory Medicine,2020,35(04):112.[doi:10.3969 ／ j.issn.1671-7414.2020.02.031]
[2]廖　强,王　娟.骨质疏松患者血清25(OH)D，骨膜素、铁蛋白水平及其与骨折发生的相关性分析[J].现代检验医学杂志,2021,36(05):138.[doi:10.3969/j.issn.1671-7414.2021.05.031]
　LIAO Qiang,WANG Juan.Serum Levels of 25(OH)D, Periostin and Ferritin in Patients with Osteoporosisand Their Correlation with Fracture[J].Journal of Modern Laboratory Medicine,2021,36(04):138.[doi:10.3969/j.issn.1671-7414.2021.05.031]
[3]黄燕红a,黄丽玲b,雷美红a,等.绝经后骨质疏松症患者血清几丁质酶壳三糖苷酶、血管活性肠肽水平与骨密度及骨代谢标志物的相关性研究[J].现代检验医学杂志,2022,37(02):179.[doi:10.3969/j.issn.1671-7414.2022.02.036]
　HUANG Yan-honga,HUANG Li-lingb,LEI Mei-honga,et al.Correlation between Serum Levels of Chitotriosidase1, Vasoactive Intestinal Peptide and Bone Mineral Density and Bone Turnover Indicators in Postmenopausal Osteoporosis Patients[J].Journal of Modern Laboratory Medicine,2022,37(04):179.[doi:10.3969/j.issn.1671-7414.2022.02.036]
[4]池继敏a,张 静a,邹 明a,等.骨折患者初期血清钙磷浓度变化与骨折部位的相关性分析[J].现代检验医学杂志,2024,39(06):218.[doi:10.3969/j.issn.1671-7414.2024.06.038]
　CHI Jimina,ZHANG Jinga,ZOU Minga,et al.Analysis of the Correlation between Serum Calcium and Phosphorus Concentration Changes and Fracture Site in Early Fracture Patients[J].Journal of Modern Laboratory Medicine,2024,39(04):218.[doi:10.3969/j.issn.1671-7414.2024.06.038]

备注/Memo

备注/Memo:
基金项目：海南省医药卫生科研基金项目（20A200008）。
作者简介：张恒林（1982-）, 男，本科，副主任医师，主要从事临床骨科疾病研究，E-mail：13648605850@163.com。
更新日期/Last Update: 2024-07-15